New directions in the pharmacotherapy of posttraumatic stress disorder.
Advances in psychopharmacology of PTSD are presented, focusing on antidepressants, adrenergic agents, antianxiety agents, and mood stabilizers. Treatment recommendations are related to recent advances in the understanding of the biology of PTSD. Pharmacotherapy of PTSD in children and adolescents is discussed, including recommended dose ranges. Recommendations are specified for pharmacotherapy of trauma survivors in the immediate aftermath of traumatic exposure, and for those with acute and chronic posttraumatic stress disorders.
Marmar
Charles R
CR
Department of Psychiatry, University of California, Department of Veterans Affairs Medical Center, San Francisco, California, USA. marmar@itsa.ucsf.edu
Neylan
Thomas C
TC
Schoenfeld
Frank B
FB
D000208:Acute Disease; D000293:Adolescent; D018674:Adrenergic Antagonists / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002648:Child; D002908:Chronic Disease; D006801:Humans; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy*
D018674:Adrenergic Antagonists; D000928:Antidepressive Agents; D014150:Antipsychotic Agents